funded in part by the Beijing Hospitals Authority of Hospitals Clinical Medicine Development of Special Funding Support(XMLX 201706);the National Science and Technology Major Project of China(2017ZX10203202-003,2017ZX10201201-001-006,and 2017ZX10201201-002-006);Beijing Science and Technology Commission(D161100002716002);the Digestive Medical Coordinated Development Center of Beijing Hospitals Authority(XXZ0302 and XXT28)。
Hepatitis B surface antigen(HBsAg)loss is an ideal treatment endpoint for patients with chronic hepatitis B(CHB).We investigated the predictive value of on-treatment HBsAg levels for HBsAg loss in hepatitis B e antige...